Skip to content

Head-down Position for Acute Ischemic Stroke With Large Artery Atherosclerosis

Head-down Position for Acute Ischemic Stroke With Large Artery Atherosclerosis: a Prospective, Random, Multi-Center, Pilot Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03744533
Acronym
HOPES2
Enrollment
96
Registered
2018-11-16
Start date
2018-11-26
Completion date
2021-08-28
Last updated
2021-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Keywords

head-down position, Large Artery Atherosclerosis

Brief summary

Currently, the guideline recommended re-perfusion such as intravenous thrombolysis and mechanical thrombectomy as the most effective treatment for acute ischemic stroke. However, the two methods are restricted by a strict time window, which greatly limits the number of the patients receiving treatment. The abundant studies have suggested that good collateral circulation can provide compensatory blood supply to save the ischemic penumbra and reduces the infarct volume, which improves the prognosis. How to improve collateral circulation in an efficient and safe way is a clinical challenge. Our recent experiment results of the animal and preliminary clinical experiments show that head-down position may significantly increase cerebral perfusion and improve neurological function. Clinically, head-down position is simple and easy to operate, and theoretically may increases brain perfusion and improve collateral circulation. A pilot randomized clinical trial is designed to investigate the effect of head-down position combined with routine rehabilitation in patients with ischemic stroke.The study is designed to explore the efficacy and safety of head-down position in patients with acute ischemic stroke

Interventions

the head position of subjects is lowered to 20 degrees in a supine position between 8:00-22:00 within 24h post-randomization as long as possible. During the procedure, when subjects feel intolerable, the head position will be elevated to lying flat (0 degree) for 5-10min, and then the above procedure is repeated. After 24h post-randomization, the head down procedures with -20 degrees in a supine position with duration of 1-1.5 hour will be performed three times daily at 9:00-11:00, 15:00-17:00 and 20:00-22:00, respectively.

guideline-based treatment

Sponsors

General Hospital of Shenyang Military Region
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patient age over 18 years 2. acute ischemic stroke within 24 h of onset 3. neurological deficit: 6≤NIHSS≤16 4. Large artery atherosclerosis etiology based on TOAST typing 5. the supplied vessel is the middle cerebral artery or internal carotid artery, and the degree of stenosis was more than 50%. 6. first stroke onset or past stroke without obvious neurological deficit (mRS≤1) 7. Signed informed consent

Exclusion criteria

1. Disturbance of consciousness 2. Hemorrhagic stroke or mixed stroke 3. Combining with severe organ dysfunction 4. Past hemorrhagic stroke 5. A history of stroke with severe sequelae 6. Planned revascularization within 3 months 7. Ischemic stroke due to surgical intervention 8. participating in other clinical trials within 3 months 9. Pregnant or lactating women 10. any inappropriate patient assessed by the researcher

Design outcomes

Primary

MeasureTime frame
proportion of modified Rankin Score of 0 to 290 days

Secondary

MeasureTime frameDescription
Proportion of modified Rankin Score of 0 to 190 days
proportion of early neurological deterioration48 hoursEarly neurological deterioration, defined as more than 4 increase in National Institute of Health stroke scale score
The occurence of stroke or other vascular events90 days
proportion of death of any cause90 days

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026